Clinical Research Directory
Browse clinical research sites, groups, and studies.
Semaglutide in Alcohol Use Disorder
Sponsor: University of Minnesota
Summary
This is a 45-week, randomized, double-blind, placebo-controlled clinical trial designed to compare the effectiveness of semaglutide versus placebo on alcohol-related outcomes among 128 adults with alcohol use disorder (AUD) and obesity.
Official title: A 45-week, Randomized, Controlled Trial of Semaglutide on Alcohol Related Outcomes in Adults With Alcohol Use Disorder and Obesity
Key Details
Gender
All
Age Range
18 Years - 65 Years
Study Type
INTERVENTIONAL
Enrollment
128
Start Date
2027-05-01
Completion Date
2033-04-30
Last Updated
2026-11-19
Healthy Volunteers
No
Conditions
Interventions
Wegovy
Participants in this arm will receive 42 weeks of treatment with semaglutide
Placebo
Participants in this arm will receive 42 weeks of placebo
Locations (1)
University of Minnesota Center for Pediatric Obesity Medicine
Minneapolis, Minnesota, United States